会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS
    • 含有吡啶化合物的配方
    • US20090325973A1
    • 2009-12-31
    • US12298652
    • 2007-04-27
    • D. Martin WattersonLinda Van EldikWenhui Hu
    • D. Martin WattersonLinda Van EldikWenhui Hu
    • A61K31/501C07D403/04
    • A61K31/506A61K31/501C07D237/20C07D401/12C07D401/14C07D403/12C07D403/14
    • The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.
    • 本发明涉及化合物,组合物和制备和使用它们的方法。 特别地,本发明提供选择的式I的哒嗪化合物独立地是氢,羟基,烷基,烯基,炔基,亚烷基,亚烯基,烷氧基,烯氧基,环烷基,环烯基,环炔基,环烷氧基,芳基,芳氧基,芳基烷氧基,芳酰基, 杂环,酰基,酰氧基,氨基,亚氨基,叠氮基,硫醇,硫代烷基,硫代烷氧基,硫代芳基,硝基,氰基,卤素,硫酸根,亚磺酰基,亚磺酰基,磺酰基,磺酸酯,亚砜,甲硅烷基,甲硅烷氧基,甲硅烷基烷基,甲硅烷硫基, -S,膦酸酯,脲基,羧基,羰基,氨基甲酰基或甲酰胺; X是任选取代的嘧啶基或哒嗪基,异构体,药用盐或其衍生物。 本发明另外涉及包含该化合物的组合物,以及使用该化合物和组合物调节细胞途径,用于治疗或预防炎性疾病,用于研究,药物筛选和治疗应用的方法。
    • 7. 发明申请
    • Protein Kinase Targeted Therapeutics
    • 蛋白激酶靶向治疗
    • US20110166153A1
    • 2011-07-07
    • US13034411
    • 2011-02-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • A61K31/501A61P29/00
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1δ以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如,CK1δ, 和上游和下游蛋白激酶)。
    • 8. 发明授权
    • Protein kinase targeted therapeutics
    • 蛋白激酶靶向治疗
    • US07919485B2
    • 2011-04-05
    • US12566153
    • 2009-09-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • A61K31/33A61K31/50C07D401/00
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1δ以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如,CK1δ, 和上游和下游蛋白激酶)。
    • 9. 发明授权
    • Protein kinase targeted therapeutics
    • 蛋白激酶靶向治疗
    • US08188096B2
    • 2012-05-29
    • US13034411
    • 2011-02-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • C07D239/42
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1δ以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如,CK1δ, 和上游和下游蛋白激酶)。
    • 10. 发明申请
    • Protein Kinase Targeted Therapeutics
    • 蛋白激酶靶向治疗
    • US20100016587A1
    • 2010-01-21
    • US12566153
    • 2009-09-24
    • D. Martin WattersonLinda J. Van Eldik
    • D. Martin WattersonLinda J. Van Eldik
    • C07D401/04
    • A61K31/50A61K45/06A61K2300/00
    • The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
    • 本发明涉及可用于治疗与蛋白激酶相关的疾病和病症的组合物和方法。 特别地,本发明涉及用于靶向与丝裂原活化蛋白激酶(MAPK)途径相关的蛋白激酶(例如p38MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或酪蛋白激酶(CK)的组合物和方法 )途径(例如CK1delta以及上游和下游蛋白激酶)以及与MAPK途径相关的疾病和病症(例如p38 MAPK,JNK,ERK以及上游和下游蛋白激酶)和/或CK途径(例如CK1delta, 和上游和下游蛋白激酶)。